Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Last Close
17.15
Aug 28 • 3:59 PM ET Dollar change+0.02 Percentage change(0.12%)
Aftermarket Close
17.15
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
6.13B
Enterprise Value
10.93B
Income
-171.00M
Sales
5.32B
Book/sh
17.86
Cash/sh
1.06
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13000
IPO
May 06, 2022
P/E
-
Forward P/E
15.83
PEG
0.39
P/S
1.15
P/B
0.96
P/C
16.20
P/FCF
43.71
EV/EBITDA
13.40
EV/Sales
2.05
Quick Ratio
1.02
Current Ratio
1.55
Debt/Eq
0.80
LT Debt/Eq
0.80
Option/Short
Yes / Yes
EPS (ttm)
-0.48
EPS next Y
1.08
EPS next Q
0.21
EPS this Y
54.68%
EPS next Y
37.29%
EPS next 5Y
41.11%
EPS past 3/5Y
- -
Sales past 3/5Y
10.62% 8.38%
EPS Y/Y TTM
37.70%
Sales Y/Y TTM
8.85%
EPS Q/Q
77.64%
Sales Q/Q
9.08%
Insider Own
88.79%
Insider Trans
-0.01%
Inst Own
10.01%
Inst Trans
-0.53%
ROA
-1.24%
ROE
-2.67%
ROIC
-1.49%
Gross Margin
56.97%
Oper. Margin
7.61%
Profit Margin
-3.21%
SMA20
0.92%
SMA50
3.57%
SMA200
3.94%
Trades
Shs Outstand
357.06M
Shs Float
40.04M
52W High
18.92 -9.33%
52W Low
13.77 24.59%
Volatility
2.22% 2.56%
ATR (14)
0.45
RSI (14)
56.52
Beta
0.55
Rel Volume
0.94
Avg Volume
426.75K
Volume
403,123
Perf Week
-0.52%
Perf Month
0.94%
Perf Quarter
9.58%
Perf Half Y
-6.28%
Perf YTD
0.41%
Perf Year
17.87%
Perf 3Y
-5.92%
Perf 5Y
-
Perf 10Y
-
Prev Close
17.13
Price
17.15
Change %
0.12%
Date Action Analyst Rating Change Price Target Change
Jul-28-26Initiated UBS Buy $21
Jan-05-26Downgrade Evercore ISI Outperform → In-line $18
Dec-11-25Upgrade Citigroup Neutral → Buy $20
Dec-02-25Upgrade Morgan Stanley Equal-Weight → Overweight $21
Oct-01-25Initiated Goldman Neutral $16
May-02-25Reiterated H.C. Wainwright Buy $20 → $15
Mar-28-25Downgrade Wells Fargo Overweight → Equal Weight $24 → $15
Dec-11-24Downgrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Aug-26-26 06:11AM
Aug-24-26 04:30PM
Aug-07-26 02:30AM
Aug-06-26 07:04AM
07:00AM
08:30AM Loading…
Jul-30-26 08:30AM
Jul-29-26 03:01PM
07:06AM
06:58AM
Jul-16-26 07:00AM
Jul-09-26 07:10PM
04:30PM
07:00AM
Jul-06-26 07:15AM
Jul-01-26 07:00AM
06:00AM Loading…
Jun-10-26 06:00AM
05:12AM
Jun-01-26 06:59AM
May-21-26 07:15AM
May-20-26 04:49PM
May-19-26 07:00AM
May-07-26 07:00AM
May-06-26 07:15AM
Apr-30-26 08:30AM
07:00AM
03:18AM
Apr-29-26 07:07AM
06:58AM
Apr-23-26 07:00AM
Apr-22-26 07:15AM
07:00AM Loading…
Apr-16-26 07:00AM
Apr-08-26 07:00AM
Apr-07-26 07:00AM
Apr-06-26 07:00AM
Mar-30-26 07:15AM
Mar-23-26 07:00AM
Mar-11-26 06:00AM
Mar-09-26 07:15AM
Feb-27-26 12:57PM
05:14AM
Feb-25-26 12:36AM
Feb-24-26 07:00AM
Feb-19-26 12:00PM
12:31AM
Feb-18-26 10:11PM
04:31PM
02:58PM
02:23PM
02:00PM
01:25PM
01:25PM
09:36AM
09:30AM
08:10AM
07:37AM
07:19AM
06:58AM
Feb-16-26 10:07PM
09:15AM
Feb-12-26 08:50AM
Feb-11-26 09:30AM
Feb-09-26 11:02PM
11:40AM
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
Jan-05-26 07:00AM
Jan-02-26 04:30PM
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
08:55AM
08:41AM
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
06:58AM
Oct-28-25 09:26AM
Oct-27-25 11:12PM
Oct-20-25 06:44PM
11:36AM
09:34AM
07:41AM
07:25AM
Oct-19-25 08:00PM
Oct-17-25 12:24PM
Oct-10-25 06:44PM
Oct-02-25 11:40AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Executive VP & CFOMr. Osama A. Eldessouky
Executive VP & Chief Legal OfficerMr. A. Robert D. Bailey
Ph.D.Dr. Yehia Hashad M.D.
President of Global Pharmaceuticals & International ConsumerMr. Andrew J. Stewart
MBAMr. Alan Waterhouse CPFA
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Munsch FrederickSVP, Controller and CAOAug 10 '26Sale16.7852,900887,66245,831Aug 12 07:06 PM
VON ESCHENBACH ANDREW C.DirectorAug 06 '26Sale16.5012,500206,25069,792Aug 10 08:57 PM
VON ESCHENBACH ANDREW C.DirectorAug 07 '26Sale16.586,059100,45863,733Aug 10 08:57 PM
Munsch FrederickFormer OfficerAug 10 '26Proposed Sale16.7852,900887,885Aug 10 04:58 PM
VON ESCHENBACH ANDREW C.Former DirectorAug 07 '26Proposed Sale16.586,059100,430Aug 07 05:43 PM
VON ESCHENBACH ANDREW C.Former DirectorAug 06 '26Proposed Sale16.5012,500206,193Aug 06 03:11 PM
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10 05:23 PM
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10 04:34 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10 04:32 PM
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04 04:18 PM
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03 04:26 PM
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03 04:24 PM
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24 04:23 PM
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24 04:16 PM
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23 04:20 PM
Last Close
5.89
Aug 28 • 3:59 PM ET Dollar change-0.14 Percentage change(-2.32%)
Aftermarket Close
5.99
Aftermarket • 7:53 PM ET Dollar change+0.10 Percentage change(1.70%)
SPRY ARS Pharmaceuticals Inc daily Stock Chart
Index
RUT
Market Cap
585.75M
Enterprise Value
538.59M
Income
-215.43M
Sales
116.93M
Book/sh
0.13
Cash/sh
1.45
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
163
IPO
Dec 04, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
5.01
P/B
46.81
P/C
4.07
P/FCF
-
EV/EBITDA
-
EV/Sales
4.61
Quick Ratio
3.28
Current Ratio
3.48
Debt/Eq
7.73
LT Debt/Eq
7.73
Option/Short
Yes / Yes
EPS (ttm)
-2.17
EPS next Y
-0.81
EPS next Q
-0.28
EPS this Y
-1.01%
EPS next Y
53.91%
EPS next 5Y
81.94%
EPS past 3/5Y
-26.04% -12.85%
Sales past 3/5Y
300.09% -
EPS Y/Y TTM
-343.67%
Sales Y/Y TTM
4.08%
EPS Q/Q
-37.56%
Sales Q/Q
114.15%
Insider Own
34.43%
Insider Trans
-0.08%
Inst Own
71.88%
Inst Trans
-4.82%
ROA
-76.53%
ROE
-210.35%
ROIC
-197.30%
Gross Margin
71.37%
Oper. Margin
-184.96%
Profit Margin
-184.24%
SMA20
1.15%
SMA50
-14.18%
SMA200
-31.74%
Trades
Shs Outstand
99.44M
Shs Float
65.20M
52W High
13.46 -56.24%
52W Low
4.91 19.95%
Volatility
5.12% 7.06%
ATR (14)
0.42
RSI (14)
46.49
Beta
1.05
Rel Volume
0.58
Avg Volume
2.04M
Volume
1,190,271
Perf Week
6.99%
Perf Month
4.62%
Perf Quarter
-35.06%
Perf Half Y
-36.53%
Perf YTD
-49.44%
Perf Year
-54.20%
Perf 3Y
-15.49%
Perf 5Y
-76.07%
Perf 10Y
-
Prev Close
6.03
Price
5.89
Change %
-2.32%
Date Action Analyst Rating Change Price Target Change
Apr-09-26Initiated Northland Capital Outperform $25
Nov-04-25Resumed Roth Capital Buy $30
Sep-04-25Initiated Roth Capital Buy $40
Mar-07-25Initiated Scotiabank Sector Outperform $30
Feb-10-25Initiated Oppenheimer Outperform $40
Aug-20-24Initiated Cantor Fitzgerald Overweight
Aug-13-24Upgrade Raymond James Outperform → Strong Buy $18 → $22
Aug-12-24Reiterated Leerink Partners Outperform $19 → $20
Jul-25-24Initiated Raymond James Outperform $18
Mar-05-24Upgrade Leerink Partners Market Perform → Outperform $6 → $18
Aug-24-26 09:35AM
Aug-17-26 11:45AM
Aug-14-26 08:30AM
01:02AM
Aug-13-26 04:01PM
01:18PM Loading…
01:18PM
Aug-12-26 03:00PM
09:24AM
Aug-10-26 07:30AM
Aug-03-26 07:30AM
Jul-07-26 04:30PM
Jun-25-26 10:42AM
10:08AM
Jun-24-26 09:43PM
08:09PM
04:05PM Loading…
04:05PM
Jun-04-26 08:00AM
May-16-26 08:30AM
May-15-26 07:01PM
06:00AM
May-13-26 08:00AM
May-07-26 08:00AM
Apr-15-26 06:05AM
Mar-27-26 08:00AM
Mar-09-26 03:01PM
07:10AM
06:00AM
Mar-06-26 07:15AM
Mar-02-26 12:23PM
10:00AM
08:00AM Loading…
Feb-23-26 08:00AM
Feb-10-26 08:00AM
Feb-02-26 01:12PM
Jan-21-26 08:00AM
Jan-09-26 12:32PM
11:28AM
03:16AM
Dec-30-25 08:10AM
Dec-29-25 08:00AM
Nov-26-25 08:00AM
Nov-10-25 04:01PM
07:05AM
06:00AM
Nov-07-25 07:19AM
Nov-06-25 09:10AM
Nov-05-25 09:15AM
Nov-04-25 09:35AM
08:00AM
Nov-03-25 02:23PM
08:00AM
07:45AM
Oct-08-25 08:00AM
Sep-29-25 04:05PM
Sep-19-25 08:00AM
Sep-17-25 11:44AM
Sep-09-25 08:11AM
Sep-08-25 08:00AM
Sep-04-25 02:54PM
Aug-28-25 08:00AM
Aug-13-25 08:15AM
07:00AM
05:26AM
Aug-12-25 09:24AM
Aug-11-25 06:55PM
Aug-08-25 01:56PM
Aug-04-25 08:00AM
Jul-31-25 05:35PM
08:50AM
Jul-30-25 10:00AM
Jul-29-25 10:00AM
Jul-18-25 12:27PM
09:25AM
Jul-15-25 12:00PM
09:55AM
08:50AM
Jun-15-25 05:26AM
Jun-11-25 09:02PM
May-27-25 08:00AM
May-15-25 03:12AM
May-14-25 10:44PM
08:15AM
07:00AM
May-13-25 09:28AM
May-08-25 05:06AM
May-05-25 08:00AM
May-04-25 04:32PM
May-02-25 08:00AM
08:00AM
Apr-30-25 06:51AM
Apr-05-25 05:31PM
Mar-23-25 07:18AM
Mar-21-25 12:16PM
12:03PM
03:03AM
12:40AM
Mar-20-25 04:04PM
03:31PM
01:29PM
01:28PM
08:25AM
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Chief Business OfficerMr. Justin Chakma
CEOMr. Donn Casale
Co-Founder & Chief Science OfficerDr. Robert Bell Ph.D.
Chief Financial OfficerMs. Kathleen D. Scott CPA
Chief Operating OfficerMr. Brian T. Dorsey M.S.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SARINA TANIMOTOOfficerAug 20 '26Proposed Sale5.9225,000147,970Aug 20 05:32 PM
RICHARD LOWENTHALOfficerAug 20 '26Proposed Sale5.9325,000148,160Aug 20 04:26 PM
SARINA TANIMOTOOfficerAug 19 '26Proposed Sale6.4525,000161,170Aug 19 04:20 PM
RICHARD LOWENTHALOfficerAug 19 '26Proposed Sale6.4550,000322,345Aug 19 04:10 PM
SARINA TANIMOTOOfficerAug 18 '26Proposed Sale6.3049,401311,192Aug 18 06:04 PM
RICHARD LOWENTHALOfficerAug 18 '26Proposed Sale6.3250,000315,885Aug 18 05:38 PM
Karas EricChief Commercial OfficerJun 12 '26Option Exercise1.5025,00037,50037,176Jun 12 08:06 PM
Karas EricChief Commercial OfficerJun 12 '26Sale10.0025,000250,00012,176Jun 12 08:06 PM
Fitzpatrick Alexander AChief Legal OfficerJun 12 '26Sale10.003,35533,55090,910Jun 12 08:04 PM
ERIC KARASOfficerJun 12 '26Proposed Sale10.0025,000250,000Jun 12 04:31 PM
ALEXANDER FITZPATRICKOfficerJun 12 '26Proposed Sale10.003,35533,550Jun 12 04:17 PM
Dorsey BrianChief Operating OfficerNov 13 '25Option Exercise0.6421,82813,97032,617Nov 14 06:43 PM
Dorsey BrianChief Operating OfficerNov 13 '25Sale8.7121,828190,05010,789Nov 14 06:43 PM
Chakma JustinChief Business OfficerNov 12 '25Option Exercise0.8430,00025,200166,380Nov 14 06:42 PM
Chakma JustinChief Business OfficerNov 12 '25Sale8.87166,3801,476,1470Nov 14 06:42 PM
BRIAN T DORSEYOfficerNov 13 '25Proposed Sale8.7121,828190,050Nov 13 04:08 PM
JUSTIN CHAKMAOfficerNov 12 '25Proposed Sale8.9130,000267,357Nov 12 05:26 PM
Chakma JustinOfficerNov 12 '25Proposed Sale8.87138,3801,227,420Nov 12 10:56 AM